Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
SYDNEY, Feb. 21, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specializing in oncology, today announced the early conclusion based on positive safety and promising clinical response findings observed to date of an important two-part Phase I trial. This investigator-initiated trial evaluated the use of paxalisib (an oral PI3K/mTOR dual inhibitor) with radiation therapy for the treatment of patients with PI3K pathway mutation brain metastases from solid tumors.
- SYDNEY, Feb. 21, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specializing in oncology, today announced the early conclusion based on positive safety and promising clinical response findings observed to date of an important two-part Phase I trial.
- After reviewing the Part II patient data generated to date, the three lead investigators have determined that the primary endpoint of the study has been reached.
- In addition, the investigators continued to observe encouraging signs of clinical response in patients in the expansion cohort.
- The increasing incidence of brain metastasis and the low response rates to existing treatments underscores the need for new treatment options.